Shares of ImmunityBio (IBRX) ticked up 3.3% to $7.46 on May 26, 2026 — the very day a critical lead-plaintiff deadline expires in securities fraud class actions tied to the company's flagship cancer treatment. The modest bounce comes after a rough stretch that saw the stock slide from $8.05 to $7.22 over the prior week, suggesting investors are cautiously repositioning now that the legal calendar's most immediate uncertainty is passing. ImmunityBio's Lawsuit Deadline Arrives — But Can Surging Drug Sales and a Major FDA Filing Outrun the Courtroom Cloud?
Shares edged up 3.3% to $7.46 as today's lead-plaintiff deadline in multiple securities class actions against ImmunityBio passed without escalation, providing a small exhale after the stock slid from $8.05 to $7.22 over the prior week. The lawsuits, the FDA's credibility concerns, and a quietly accelerating commercial business are now locked in a tug-of-war for this stock's direction.
The Lawsuit Traces Back to One Podcast That Cost Shareholders $2 Billion
On January 19, 2026, a direct-to-consumer podcast aired featuring founder Patrick Soon-Shiong, who claimed the company's bladder cancer drug "actually can treat all cancers."
On March 24, the FDA sent a warning letter calling the company's promotional claims "especially concerning from a public health perspective."
The stock cratered over 21% that day, erasing nearly $2 billion in market value.
The class action covers investors who bought shares between January 19 and March 24, 2026. Today's deadline determines which investor group will lead the litigation — a procedural step, but one that locks in the legal adversary ImmunityBio will face.
The Actual Drug Business Keeps Getting Bigger
Beneath the legal noise, revenue is climbing fast. Q1 2026 net product revenue hit approximately $44.2 million, a 168% increase over Q1 2025 , and a 15% sequential jump from Q4 2025's $38.3 million.
The company ended Q1 with $380.9 million in cash. For a biotech still burning roughly $72 million a quarter in free cash flow, that cash pile provides a multi-quarter runway.
A Label Expansion Could Dramatically Widen the Market
On May 19, the FDA accepted a supplemental application to expand the drug's approval to papillary-only bladder cancer patients — the larger segment of the eligible population.
Roughly 85% of the 64,000 Americans diagnosed annually with this type of bladder cancer present with papillary disease , and the FDA set a decision date of January 6, 2027. Approval would multiply the addressable patient pool several times over.
Analysts Are Bullish, but the Stock Price Isn't Listening
Five analysts carry a "Strong Buy" consensus with a $14.40 price target — nearly double today's price. Yet at $7.46, the stock sits 40% below its $12.43 52-week high, reflecting how deeply the FDA warning and lawsuits have dented investor confidence. Until the litigation picture clarifies and promotional credibility is restored, the discount is unlikely to close — no matter how fast the revenue line grows.